SBWire

The Tropical Diseases Partnering 2009-2014 provides understanding and access to the tropical diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

Liver Disease Partnering 2009-2014 provides understanding and access to the liver disease partnering deals and agreements entered into by the worlds leading healthcare companies.

The Chronic Kidney Disease Partnering 2009-2014 provides understanding and access to the chronic kidney disease partnering deals and agreements entered into by the worlds leading healthcare companies.

The Sensory Organ Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter sensory organ partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors sensory organ technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

GlobalData's clinical trial report, "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Arrhythmia Partnering 2009-2014 provides understanding and access to the arrhythmia partnering deals and agreements entered into by the worlds leading healthcare companies.

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

Obesity Partnering 2009-2014 report provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare companies.

The Genitourinary Symptoms Partnering 2009-2014 provides understanding and access to the genitourinary symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

Preventative Medicine Partnering 2009-2014 report provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The Bone Fracture Partnering 2009-2014 report provides understanding and access to the bone fracture partnering deals and agreements entered into by the worlds leading healthcare companies.

Signum Biosciences, Inc. - Product Pipeline Review - 2014

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.

GlobalData's clinical trial report, "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Renal Cell Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Ocular Melanoma Global Clinical Trials Review, H1, 2014" provides data on the Ocular Melanoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ocular Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ocular Melanoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Pleural Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Pleural Mesothelioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Pleural Mesothelioma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" provides data on the Opioid-Induced Constipation (OIC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid-Induced Constipation (OIC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid-Induced Constipation (OIC). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Malignant Fibrous Histiocytoma Of Bone Global Clinical Trials Review, H1, 2014" provides data on the Malignant Fibrous Histiocytoma Of Bone clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Fibrous Histiocytoma Of Bone. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Malignant Fibrous Histiocytoma Of Bone. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Oral Mucositis Global Clinical Trials Review, H1, 2014" provides data on the Oral Mucositis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Mucositis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Mucositis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Refractory Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Malaysia". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Malaysia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

CEL-SCI Corporation today announced that during the month of April 2014 the Company enrolled 21 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial for its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection). This marks a substantial increase over the previous monthly record of 14 patients in March 2014.

Colon Carcinoma - Pipeline Review, H1 2014